Youth-focused Strategies to Promote Adherence to Pre-exposure Prophylaxis Among Youth At-risk for HIV in Thailand (YouthPrEP)

January 21, 2020 updated by: Wipaporn Natalie Songtaweesin, MD., Chulalongkorn University
A randomized controlled clinical trial looking at the effect of use of a mobile phone application in addition to standard care compared to standard care alone at a youth-friendly clinic in young men who have sex with men and transgender women aged between 15-19 years at risk of HIV on PrEP adherence.

Study Overview

Detailed Description

OBJECTIVES

Primary Objectives:

To study PrEP adherence in adolescent MSM who are at high risk of HIV acquisition.

Secondary Objectives:

To study

  1. Rates of HIV infection
  2. Rates of sexually transmitted infections (STIs)
  3. Sexual risk taking behaviours In adolescent MSM who are at high risk of HIV infection.

HYPOTHESES:

  1. The investigators hypothesize that youth-focused interventions will produce superior adherence to PrEP from 50% with standard interventions to 70% with youth focused interventions.
  2. The investigators hypothesize that adherence to PrEP varies by the level of risk behavior one perceives. Participants who take higher risk behaviors will be more likely to adhere to PrEP than participants who have lower risk behaviors. STIs are expected to be more common among participants with higher levels of adherence if they are participants who have higher risk behaviors.

RESEARCH DESIGN:

Randomised control trial, behavioural intervention

RESEARCH METHODOLOGY

  1. Study population Volunteers aged 15 to under 20 years at high risk of HIV infection receiving PrEP under the 'Princess PrEP' project
  2. Inclusion Criteria

    • Adolescent men who have sex with men
    • At high risk of HIV infection (have at least one of the following)

      • More than 1 sexual partner in the last 6 months
      • Irregular condom use during sexual intercourse
      • HIV positive sexual partner
    • Age 15 to under 20 years old
    • A desire to take PrEP to prevent HIV infection
    • Tested HIV negative within 1 month of enrolment
    • Able to provide written consent or assent to take part in the clinical trial
  3. Exclusion criteria Signs or symptoms of acute retroviral syndrome that cannot be confirmed to be due to alternate causes, including unremitting fevers, headaches, myalgia, fatigue, and lymphadenopathy
  4. Study recruitment

    • Eligible persons presenting to the Thai Red Cross Anonymous Clinic (TRCARC) or its affiliated community based organizations (Rainbow Sky Association Thailand (RSAT) Ramkamhaeng, Sex Workers in Action Group (SWING) Bangkok will be asked by counsellors on their interest to join the study.
    • Number of participants to be studied: 200
  5. Informed consent process/ informed assent The research doctor will explain to potential participants about the purposes of the study and allow them to ask any questions they may have on it, and will be given time to make their decision. If a participant chooses to join the study, they will be asked for their written consent/assent and a copy of the informed consent/assent form given to them.

    • Participants aged between 15 and 18 will be asked for assent. As this is a study on sexual health where disease prevention is of utmost concern, parental consent will not be asked for.
    • Participants aged 18 to 19 will be asked for consent.
  6. Study procedure After informed consent or assent, all youth will commence once daily TFV/FTC 200/300mg. Volunteers will be randomized into arms 1 (standard intervention) or 2 (novel intervention strategy). Both groups will receive youth-focused counselling by trained counsellors and have access to an adolescent-friendly sexual health promotion website and social media page where they can get in contact with counsellors, doctors, fellow adolescents and function as a platform through which they can learn about good sexual health practices. Adolescents in arm 2 (novel intervention strategy) will also receive access to a mobile phone application.

Youth-focused counselling Counsellors will provide counselling that is friendly, non-judgmental and utilize motivational interviewing techniques where sessions are more collaborative rather than didactic.

Mobile Phone Application

  • Password protection will ensure user privacy
  • Will allow users to input weekly data on their:

    • Sexual risk e.g. no sexual activity, sex with condoms, sex without condoms
    • PrEP use e.g. whether or not participants take their PrEP
  • The application will calculate a percentage of protection users have based on their data entry
  • Points can be accumulated for application use, data input to the application, for attending appointments and also for normal STI and HIV screening results. Points can be redeemed for cash
  • The overall goal of the application is to increase participant awareness of self-risk and motivation to protect themselves against HIV and STI infection

Participants will be followed up at months 1, 3 and 6. At each visit, participants will complete a questionnaire on drug adherence and sexual health risk behaviours.

STI testing will be done as an indirect marker of condom use at visits 1 and 6. This will involve blood testing for syphilis serology and nucleic acid amplification testing for gonorrhea, and chlamydia on swab samples.

HIV testing will be done at all visits. TFV-DP DBS will be done at months 1, 3 and 6 to look at correlation of self-reported and actual measured PrEP compliance.

Drug Concentrations will be measured using the TFV-DP DBS at the Program for HIV Prevention and Treatment (PHPT), Chiang Mai. TFV-DP DBS levels ≥ 700 fmol/punch will be taken as adherence

Study Type

Interventional

Enrollment (Actual)

200

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Bangkok, Thailand, 10330
        • Thai Red Cross AIDS Research Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

15 years to 19 years (ADULT, CHILD)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Male

Description

Inclusion Criteria:

  • Adolescent men who have sex with men
  • At high risk of HIV infection (have at least one of the following)

    • More than 1 sexual partner in the last 6 months
    • Irregular condom use during sexual intercourse
    • HIV positive sexual partner
  • Age 15 to under 20 years old
  • A desire to take PrEP to prevent HIV infection
  • Tested HIV negative within 1 month of enrolment
  • Able to provide written consent or assent to take part in the clinical trial

Exclusion Criteria:

  • Signs or symptoms of acute retroviral syndrome that cannot be confirmed to be due to alternate causes, including unremitting fevers, headaches, myalgia, fatigue, and lymphadenopathy

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: PREVENTION
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
EXPERIMENTAL: Novel Intervention
Use of a mobile phone application to support PrEP adherence in addition to youth-friendly counselling and services
Mobile phone application with weekly input channels for PrEP use, condom use, number of sex partners and sex acts and a calculation of self-HIV risk feedback scoring. Scoring system for attendance of visits, normal blood tests and use of application. Points redeemable for cash. Optional alarm system to remind to take medications and attend visits.
NO_INTERVENTION: Standard Intervention
Use of a mobile phone application to support PrEP adherence in addition to youth-friendly counselling and services

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
PrEP Adherence
Time Frame: Weekly self-reported adherence for a period of 6 months following randomization
Self-Reported Adherence
Weekly self-reported adherence for a period of 6 months following randomization
PrEP Adherence at 3 months
Time Frame: Measured at month 3 (measure of 17 day half life of TDF-DP)
Measured Serum TDF-DP Level (from dried blood spots)
Measured at month 3 (measure of 17 day half life of TDF-DP)
PrEP Adherence at 6 months
Time Frame: Measured at month 6 (measure of 17 day half life of TDF-DP)
Measured Serum TDF-DP Level (from dried blood spots)
Measured at month 6 (measure of 17 day half life of TDF-DP)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
HIV infection rates
Time Frame: duration of study (6 months)
seroconversion rates whilst on PrEP during study
duration of study (6 months)
Rates of Urethral Neisseria gonorrhea
Time Frame: duration of study (6 months)
Rates of Urethral Neisseria gonorrhea via Nucleic Acid Amplification Screening (NAAT) urine testing
duration of study (6 months)
Behaviour Risk-Taking
Time Frame: duration of study (6 months)
Composite calculated score of risk taking based on self-reported condom use, PrEP tablets taking, number of sexual partners in preceding one month. Scores will equate to risk levels of low, medium, high and very high.
duration of study (6 months)
Rates of Anal Neisseria gonorrhea
Time Frame: duration of study (6 months)
Rates of Anal Neisseria gonorrhea via Nucleic Acid Amplification Screening (NAAT) from anal swab samples
duration of study (6 months)
Rates of Urethral Chlamydia trachomatis
Time Frame: duration of study (6 months)
Rates of Urethral Chlamydia trachomatis via Nucleic Acid Amplification Screening (NAAT) urine testing
duration of study (6 months)
Rates of Anal Chlamydia trachomatis
Time Frame: duration of study (6 months)
Rates of Anal Chlamydia trachomatis via Nucleic Acid Amplification Screening (NAAT) from anal swab samples
duration of study (6 months)
Rates of Syphilis Infection
Time Frame: duration of study (6 months)
Rates of positive treponemal blood tests
duration of study (6 months)
Rates of Hepatitis B infection
Time Frame: At initial project visit (month 0)
Rates of positive HbsAg blood tests
At initial project visit (month 0)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ACTUAL)

March 1, 2018

Primary Completion (ACTUAL)

December 15, 2019

Study Completion (ACTUAL)

December 15, 2019

Study Registration Dates

First Submitted

December 8, 2018

First Submitted That Met QC Criteria

December 17, 2018

First Posted (ACTUAL)

December 19, 2018

Study Record Updates

Last Update Posted (ACTUAL)

January 23, 2020

Last Update Submitted That Met QC Criteria

January 21, 2020

Last Verified

January 1, 2020

More Information

Terms related to this study

Other Study ID Numbers

  • 2017/472-SON

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on HIV Prevention

Clinical Trials on 'Project Raincoat' Mobile Phone Application

Subscribe